Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | ALKEM Alkem Laboratories Limited Pharma · Mid | APLLTD Alembic Pharmaceuticals Limited Pharma · Mid | GLAXO GlaxoSmithKline Pharmaceuticals Limited Pharma · Large | AJANTPHARM Ajanta Pharma Limited Pharma · Large |
|---|---|---|---|---|
| Final Score | 51 | 35 | 60 | 54 |
| Verdict | FAIR VALUE | WATCHLIST | UNDERVALUED | FAIR VALUE |
| Style | Financial Turnaround | WATCHLIST | Premium Compounder | Premium Compounder |
| Piotroski | 8/9 | 8/9 | 8/9 | 8/9 |
| Valuation | 4/30 | 6/30 | 4/30 | 4/30 |
| Growth | 13/25 | 4/25 | 11/25 | 13/25 |
| Quality | 13/20 | 2/20 | 20/20 | 17/20 |
| Balance Sheet | 10/15 | 13/15 | 12/15 | 11/15 |
| Cash Flow | 6/10 | 5/10 | 7/10 | 4/10 |
| Price | ₹5,322.5 | ₹731.5 | ₹2,194.7 | ₹3,017.2 |
| P/E | 26.30 | 20.10 | 36.20 | 35.10 |
| P/B | 4.63 | 2.58 | 16.30 | 8.20 |
| ROE | 18.90% | 13.40% | 48.40% | 25.40% |
| ROCE | 21.20% | 12.60% | 65.10% | 32.30% |
| Debt / Equity | 0.10 | 0.25 | 0.02 | 0.06 |
| FCF Yield | 2.81% | 1.89% | 3.51% | 0.27% |
| Dividend Y | 0.84% | 1.48% | 2.61% | 0.94% |
| Altman Z | 7.79 | 5.24 | 8.62 | 8.92 |
| Promoter % | 51.20% | 69.74% | 75.00% | 66.25% |
| Mkt Cap (₹Cr) | 64048.00 | 14654.00 | 36995.00 | 37091.00 |
| Graham # | ₹2,237.67 | ₹472.47 | ₹429.38 | ₹829.71 |
| Fair PE | 30.3 | 4.2 | 42.0 | 42.3 |
| MoS % | +8.7% | -406.2% | +14.6% | +15.6% |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startALKEM94
APLLTD70
GLAXO86
AJANTPHARM105